MLchartDataset catalogue

anti-EGFRvIII-CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E

Term · Oncology and biomedicine · MLC-T-ONC-010619

A preparation of autologous human T lymphocytes transduced with a CARv3-TEAM-E lentiviral vector encoding for an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) and a T-cell-engaging antibody molecule (TEAM) which comprises a bispecific T-cell engager (BiTE) against EGFR and the T-cell signaling domain CD3, with potential immunostimulatory and antineoplastic activities. Upon administration via Ommaya reservoir of the anti-EGFRvIII CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E, the lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces and the BiTE binds to CD3 on bystander T cells; thereby killing EGFRvIII-expressing tumor cells through the administered CAR-T cells and wild-type (WT) EGFR-expressing tumor cells by bystander T cells, respectively. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.

Table 1. Record
IdentifierMLC-T-ONC-010619
FieldOncology and biomedicine
Synonymsautologous CARv3-TEAM-E-transduced T cells; autologous CARv3-TEAM-E-transduced T lymphocytes
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010619",
  "term": "anti-EGFRvIII-CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous human T lymphocytes transduced with a CARv3-TEAM-E lentiviral vector encoding for an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) and a T-cell-engaging antibody molecule (TEAM) which comprises a bispecific T-cell engager (BiTE) against EGFR and the T-cell signaling domain CD3, with potential immunostimulatory and antineoplastic activities. Upon administration via Ommaya reservoir of the anti-EGFRvIII CAR-CD3/EGFR BiTE-transduced autologous T lymphocytes CARv3-TEAM-E, the lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces and the BiTE binds to CD3 on bystander T cells; thereby killing EGFRvIII-expressing tumor cells through the administered CAR-T cells and wild-type (WT) EGFR-expressing tumor cells by bystander T cells, respectively. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.",
  "synonyms": [
    "autologous CARv3-TEAM-E-transduced T cells",
    "autologous CARv3-TEAM-E-transduced T lymphocytes"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-egfrviii-car-cd3-egfr-bite-transduced-autologous-t-lymphocytes-carv3-team-e/"
}

Record 1,715 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.